Grifols GIFLF
NASDAQ GIFLF
$11.08 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Grifols (GIFLF) Total Non-Current Liabilities (2009 - 2025)

Grifols' (GIFLF) quarterly Total Non-Current Liabilities came in at $40.7 million in Q4 2025, down 2.24% on a YoY basis from $41.7 million in Q4 2024, and down 2.24% quarter-over-quarter from $41.7 million in Q4 2024.

Analysis

Grifols (GIFLF) Total Non-Current Liabilities (2009 - 2025) Analysis & Trends

Grifols (GIFLF) has reported Total Non-Current Liabilities for 17 consecutive years, with $40.7 million the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 2.24% year-over-year to $40.7 million; the trailing twelve-month figure through Dec 2025 stood at $40.7 million (down 2.24% YoY), and the FY2025 full-year result was $39.5 million, down 29.39% from the prior year.
  • Total Non-Current Liabilities declined to $40.7 million in Q4 2025 per GIFLF's latest filing, from $41.7 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $57.5 million in Q4 2022 and bottomed at $35.9 million in Q4 2021.
  • Historically, Total Non-Current Liabilities has averaged $45.5 million across 5 years, with a median of $41.7 million in 2024.
  • The sharpest annual moves came in 2021 and 2024: Total Non-Current Liabilities soared 169.66% in 2021, then declined 18.98% in 2024.
  • Over 5 years, Total Non-Current Liabilities stood at $35.9 million in 2021, then surged by 59.98% to $57.5 million in 2022, then declined by 10.51% to $51.4 million in 2023, then decreased by 18.98% to $41.7 million in 2024, then decreased by 2.24% to $40.7 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $40.7 million, $41.7 million, and $51.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn 81.11 Bn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn 36.04 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn 5.92 Bn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn 7.74 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn 40.00 Mn
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn 3.92 Bn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn 4.20 Bn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn 12.42 Bn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn 378.37 Mn
10 Grifols 7.54 Bn 9.09 Bn 3.33 Bn 40.74 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 40.74 Mn
Dec 31, 2024 41.68 Mn
Dec 31, 2023 51.44 Mn
Dec 31, 2022 57.48 Mn
Dec 31, 2021 35.93 Mn
Dec 31, 2020 13.32 Mn
Sep 30, 2020 8.52 Bn
Mar 31, 2020 8.12 Bn
Dec 31, 2019 58.79 Mn
Sep 30, 2019 8.18 Bn
Dec 31, 2018 7.45 Bn
Sep 30, 2018 7.61 Bn
Jun 30, 2018 7.69 Bn
Mar 31, 2018 8.96 Bn
Dec 31, 2017 7.43 Bn
Jun 30, 2017 7.29 Bn
Dec 31, 2016 5.75 Bn
Sep 30, 2016 5.70 Bn
Jun 30, 2016 5.82 Bn
Mar 31, 2016 97.28 Mn